While the FDA's warning does not directly target any specific company, it casts a shadow over the health technology sector, particularly those companies that are exploring or have invested in the development of non-invasive glucose monitoring technologies. This could lead to negative investor sentiment towards these companies, potentially affecting their stock prices in the short term. The SPY ETF, which includes a broad range of companies, including those in the health technology sector, might see a slight negative impact due to this announcement.